SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp futures rebound after Fridays selloff has turned the discussion from Black Monday crash warnings to whether the market can sustain the bounce. Traders debate whether it reflects genuine dip-buying or a fragile overnight short-covering move, with some linking optimism to possible Russia-Ukraine developments and easing oil prices while others expect a reversal.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The prolonged wait for SELLASs REGAL Phase 3 trial to reach its 80th death eventand the subsequent final analysisdominates discussion; the last disclosed count was 78, and the company has not confirmed the trigger. Bulls interpret the delay and quiet period as a possible sign of longer survival and speculate about an ASH data reveal, while skeptics see uncertainty around the trial and disclosure timeline; the stocks sharp decline has intensified that debate.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp tech- and AI-led selloff has put QQQ under pressure, while a strong rebound in futures prompted traders to debate whether the bounce can hold or is a bull trap. Black Monday anniversary crash warnings amplified the volatility, but many traders dismissed them as the rebound gathered momentum.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares are under pressure amid IPO lockup expirations that make additional insider and employee shares eligible for sale, compounded by a broader AI and semiconductor selloff. Traders disagree on whether the added supply and concerns about valuation, scalability, and customer concentration will prolong the decline or whether the selloff is overdone given Cerebras inference technology.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in a broad neocloud and AI-infrastructure selloff as investors question the sectors debt-fueled expansion, financing costs, and path to returns. Traders are split between viewing the decline as an overdone pullbackoften arguing Nebius is better positioned than some peersand expecting further downside amid sector-wide risk concerns.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

ESMO updates on Iovances lifileucel program are driving attention, especially mature frontline melanoma data for lifileucel plus pembrolizumab that traders view as showing durable activity. The reaction is mixed: some see the results as supportive of the ongoing Phase 3 trial, while others argue the small cohort and largely consistent readout limit how much is new; early sarcoma results are also being watched cautiously pending larger-trial validation.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is drawing attention after a sharp semiconductor selloff, with its 3 leverage magnifying losses and the subsequent rebound. Traders are split between buying an oversold bounce and expecting more downside amid concerns about AI spending and debt, Chinese competition, and persistent inflation.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

A strong quarterly report and upbeat cloud outlook drove a sharp rally, with traders also discussing Atlassians AI products as evidence that enterprise software can benefit from rather than be displaced by AI. Some see cloud demand and improving execution supporting the recovery, while others warn the run-up is overextended and point to valuation and AI-related seat-compression risks.

Roundhill ETF Trust - Roundhill Memory ETF

DRAM is drawing attention amid a sharp selloff in memory stocks, with traders citing fears that Chinas CXMT advances could add supply and pressure pricing, alongside doubts about AI data-center demand and financing. The debate pits those bearish concerns against dip-buyers who argue AI-driven memory demand remains durable; no single cause is confirmed as the sole driver.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visas push into stablecoin payments is drawing attention alongside its move to fresh highs, with traders also citing momentum and China-market access as positives. The reaction is broadly bullish, though some warn the stock looks overextended or expensive.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2026 on Thursday, October 29, 2026, before the U.S. financial markets open. Management will provide an update on the...

If You Invested $1000 In Alnylam Pharmaceuticals Stock 15 Years Ago, You Would Have This Much Today

Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 15 years by 12.41% on an annualized basis producing an average annual return of 25.61%. Currently, Alnylam Pharmaceuticals has a marketread more...

Interesting ALNY Put And Call Options For September 2027

Investors in Alnylam Pharmaceuticals Inc (Symbol: ALNY) saw new options become available today, for the September 2027 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 339 days until expiration the newly av...

argenx Meets Primary Endpoint in Phase II Celiac Disease Study

ARGX's FB102 achieves its primary endpoint in a phase II celiac disease study, paving the way for late-stage development despite a nearly 12% stock drop.

EDIT Set to Begin First-in-Human Study in Hypercholesterolemia 

Editas Medicine gains approval to launch the first-in-human phase I/II study of EDIT-401 in Australia, targeting LDL cholesterol through gene editing.

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio

VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.

ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study 

argenx shares tumble 12% after discontinuing its late-stage Sjogren's disease study, while positive FB102 data in celiac disease offer a contrasting pipeline development.

Here's Why You Should Add LPCN Stock to Your Portfolio Now

Lipocine's Tlando royalties, Brlizio's phase III trial and broader pipeline offer multiple potential growth drivers and catalysts.

Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash

RARE enters into an agreement to sell a Rare Pediatric Disease PRV for $210M, adding non-dilutive cash as it advances rare-disease therapies.

ETON Stock Surges 108% in Six Months: Here's What You Need to Know

Eton's sales surge, raised 2026 outlook and expanding rare-disease portfolio are boosting confidence in its growth.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002, and is headquartered in Cambridge, MA.

Alnylam Pharmaceuticals Inc

IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY

Equity

Bearish Sentiment

Track ALNY stock price, charts, news and real-time market activity on Stocktwits. Join the ALNY message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Alnylam Pharmaceuticals Inc stock.

ALNY Stock Price Today - Alnylam Pharmaceuticals Inc News, Charts, Retail Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$231.83
Prev Close	$234.03
Open	$235.18
Dividend Yield	0.00%
50-Day Moving Average	$238.41
Beta	0.75
Avg. Volume	1.48M
PE Ratio	39.14

52-Week High	$495.55
52-Week Low	$197.81
Market Capitalization	$31.02B
EPS (Annual)	$2.33
Price to Book	22.90
Revenue Per Employee	$1.49M

Feed

News

Sentiment

Earnings

Fundamentals

Info

ALNY Fundamentals